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1. Introduction 
The signal transducers and activators of transcription, STAT proteins, were originally 
discovered in interferon (IFN)-regulated gene transcription in the early 1990’s. Since then, a 
number of cytokines have been recognized to activate various STAT proteins. STATs 
constitute a family of seven transcription factors, STAT1α/β, STAT2, STAT3α/β, STAT4, 
STAT5A, STAT5B and STAT6, that transduce signals from a variety of extracellular stimuli 
initiated by different cytokine families that aside from interferons (interferon α, β and γ) 
include gp130 cytokines, i.e., IL-6, IL-12, IL-23 and γC cytokines that include IL-2, IL-15 and 
IL-21 [1 ].  
Although structurally similar, the seven STAT family members possess diverse biological 
roles and are engaged in numerous processes from embryonic development, organogenesis, 
cell differentiation to regulation of immune processes. Awareness of their important role in 
regulation of cell proliferation, differentiation and survival has spurred interest in 
investigation of their activity in malignant transformation [2]. Evidence has now 
accumulated that confirms their role in pathogenesis of leukemias and numerous solid 
tumors [3] (Table1). 
Aside from cytokine receptors, STATs are also activated by receptors for growth factors 
(family of tyrosine kinase receptors) that include receptors for epidermal growth factor - 
EGFR, platelet-derived growth factor - PDGF, hepatocyte growth factor - HGF and colony-
stimulating factor 1- CSF-1 receptors that possess an intrinsic tyrosine kinase activity [4]. 
These receptors may activate STAT proteins either directly or indirectly by means of JAK 
kinase proteins. Also, free intracellular enzymes, i.e., non-receptor tyrosine kinases that 
include oncogenes src and bcr-abl activate various STATs [5].  
 
Oncogene and Cancer – From Bench to Clinic 456 
Different biological processes regulated by STAT proteins
Embryonic development    
Organogenesis and function    
Cells proliferation     
Cell differentiation, growth and apoptosis 
Innate and adoptive immunity    
Inflammation     
Angiogenesis     
Wound healing     
Malignant transformation       
Table 1. Role of STATs in the organism 
Interaction of cytokines and their specific receptors directly activates free intracellular non-
receptor enzymes, Janus kinases, and subsequently, latent STAT transcription factors that 
through the JAK/STAT signaling pathway lead to the expression of numerous genes that 
regulate important cellular processes. It is of importance that numerous cytokines, growth 
factors in different cell types activate STAT1, STAT3 and STAT5 and mediate broadly 
diverse biologic processes that control cell homeostasis. On the other hand, STATs such as 
STAT4 and STAT6 have a more specific role and they are engaged in T helper cell 
differentiation and maintenance of equilibrium between Th1 and Th2 immune response [6]. 
Defects in STAT molecules can lead to serious defects in development and to fetal death 
indicating the importance of JAK/STAT pathway in normal cell development. Defects in the 
JAK/STAT signaling pathway are often encountered in primary malignant tumors, as well 
as in peripheral blood lymphocytes [7,8,9] and STAT3 has been the first to be identified as a 
potential oncogene [2] (Fig.1). 
Given the critical roles of STAT proteins such as activation of pro-inflammatory and anti-
proliferative processes by STAT1 and control of cell-cycle progression and apoptosis by 
STAT3 and STAT5 it has been established in many studies that their dysregulation can 
contribute to oncogenesis [10] by increasing proliferation and slowing-down apoptosis. In 
this sense, studies show that STAT3 is activated in a majority of breast and prostate cancers, 
and that STAT3 inhibition using RNA interference or a dominant negative genotype leads to 
reduced cell proliferation, survival, and induces wound healing. Further, blocking STAT3 
interaction with EGFR using peptide aptamers has been shown to reduce tumor growth. On 
the other hand, STAT1 has been primarily defined as a tumor suppressor gene and its 
inactivation was associated with malignant transformation. Initially STAT proteins were 
extensively studied in leukemias, but later their role in the development of different solid 
tumors has been shown. 
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Figure 1. Mechanisms of STAT signaling upon activation of different tyrosine kinase (TK) signaling 
pathways that can induce activation of STAT proteins. In the case of growth factors like EGF that bind 
to receptor tyrosine kinases (RTKs), the receptor can directly phosphorylate STATs and/or indirectly 
induce STAT phosphorylation. Also, cytokines, like IL-6, that bind to cytokine receptors lacking intrinsic 
TK activity undergo ligand-induced dimerization of the receptor that results in phosphorylation of 
receptor-associated JAK kinases. JAKs in turn phosphorylate the receptor cytoplasmic tails on tyrosine, 
providing “docking sites” for recruitment of monomeric STATs. JAKs then phosphorylate the recruited 
STAT proteins on tyrosine, inducing dimerization, nuclear translocation, and DNA-binding activity. Other 
non-receptor bound free intracellular enzymes named non-receptor TKs such as SRC family kinases are 
also involved and can directly induce STAT activation. Once in the nucleus, activated STAT proteins bind 
to specific DNA sequences in the promoters of genes and induce their expression. In the context of 
oncogenesis, constitutive activation of TK-STAT signaling pathways induces elevated expression of genes 
involved in controlling cellular processes such as cell proliferation and survival. 
Aside from their role in the development of tumors STAT1,3 and 5 can be considered as 
molecular markers for early detection of certain types of tumors, as well as prognostic 
factors for determining tumor aggressiveness and predictors of response to various types of 
therapy. Novel data also indicate functional interplay between several activated STATs and 
association of STAT5 with certain well differentiated tumors with favorable prognosis 
[11].Based on numerous new data it appears that dysregulation of STAT signaling pathway 
may serve as a basis for designing novel targeted molecular therapeutic strategies that hold 
great potential for the treatment of solid tumors and leukemias. 
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1.1. Structural and functional characteristics of STATs 
STATs share structurally and functionally conserved domains that include the amino-
terminal domain (NH2), the coiled-coiled domain (CCD), the DNA binding domain (DBD), 
the linker domain and the SH2/tyrosine activation domain [12]. In contrast, the carboxyl-
terminal transcriptional activation domain (TAD) is quite divergent and contributes to STAT 
specificity (Table 2). 
Functionally, the amino-terminal domain of STAT molecules is the oligomerization domain 
that interacts with other proteins and mediates oligomerization of STAT dimers to form 
tetramers [13]. The DNA binding domain defines the DNA-binding specificity to tandem 
GAS elements and each STAT component of the dimer recognizes bases in the most 
proximal half of GAS and mediates distinct signals for specific ligands. 
SH2 domain, located near the C-terminal domain, plays an important role in signaling 
through its capacity to bind to specific phosphotyrosine motifs and to mediate specific 
interactions. Consistent with this, it is the most highly conserved STAT domain. The ability 
of this SH2 domain to recognize specific phosphotyrosine motifs plays an essential role in 
three STAT signaling events that include recruitment to the phosphorylated cytokine 
receptor through recognition of specific receptor phosphotyrosine motifs, association with 
the activating JAKs, as well as STAT homo- or heterodimerization [14]. 
 
Domain Role 
NH2-terminal domain 
   Oligomerization domain
Interacts with other proteins and mediates oligomerization of 
STAT dimers to form tetramers 
DNA binding domain Defines the DNA-binding specificity and mediates distinct 
signals for specific ligands 
SH2 domain Mediates specific interactions between STAT and receptors, 
STAT and JAK and STAT homo or hetero dimerization 
COOH-terminal domain 
   Transcription activation  
domain (TAD) 
TAD regulates  the transcriptional activity of STATs and 
provides  specificity 
   Tyrosine residue Phosphorylation site in the COOH-terminal domain that 
regulates the DNA-binding activity of all STATs. On 
phosphorylation mediates STAT dimerization 
   Serine residue A second phosphorylation site in the C-terminal domain 
Table 2. STAT structure 
Close to the SH2 domain the critical tyrosine residue is located that is required for SH-
phosphotyrosine interaction and thus STAT activation. This tyrosine residue is then rapidly 
phosphorylated by the active JAK determining STAT dimerization by binding to the SH2 
domain of the reciprocal STAT molecule.  
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A conserved serine residue in the C-terminal domain of STAT1,3, and 5 is a second 
phosphorylation site that enhances DNA binding affinity and transcriptional activity [15]. It 
has been determined that the transcriptional activity of several STATs can be modulated 
through serine phosphorylation. Serine phosphorylation appears to enhance the 
transcription of some, but not all target genes. It has been suggested that serine 
phosphorylation may alter the affinity for other transcriptional regulators like 
minichromosome maintenance complex component 5 (MCM5) and BRCA1 [12].  
C-terminal domain also encodes transcriptional activation domain (TAD) that contributes to 
STAT specificity and is thought to be involved in communication with transcriptional 
complexes, to regulate the transcriptional activity of STATs and provide functional 
specificity. Altered serine phosphorylation site associated with the c-terminal 
transactivation domain truncation of STAT1 and STAT3 reduces their transcriptional 
capacity by 20% [16]. Moreover, a c-TAD truncation leads to the α and β isoforms of STAT 
proteins that are biologically significant and appear to affect the cell’s fate [13].  
1.2. Mechanism and regulation of STAT protein function 
When ligands bind to their receptors they initiate a cascade of intracellular phosphorylation 
events. However, members of the hematopoietin receptor family possess no catalytic kinase 
activity. Rather, they rely on members of the JAK family of tyrosine kinases to provide this 
activity. JAKs are constitutively associated with a proline-rich domain of these receptors 
[17]. Upon ligand stimulation, receptors undergo the conformational changes that bring 
JAKs into proximity of each other, enabling activation by trans-phosphorylation [18]. Once 
activated, JAKs mediate the described signal transduction. Several studies have also 
suggested that JAKs associate with the receptor tyrosine kinases [12]. The phosphorylated 
JAKs, in turn, mediate phosphorylation at the specific receptor tyrosine residues, which then 
serve as docking sites for STATs and other signaling molecules. Once recruited to the 
receptor, STATs also become phosphorylated by JAKs, on a single tyrosine residue. The 
position of these tyrosines in STAT molecule is specific for each member of STAT family of 
proteins, such as Tyr 701 for STAT1, Tyr690 for STAT2, Tyr 705 for STAT3, Tyr 693 for 
STAT4, Tyr 694 for STAT5, and Tyr 641 for STAT6. Their phosphorylation mediates STAT 
dimerization which occurs by binding of the SH2 domain of one molecule with the domain 
containing the phosphotyrosine of another STAT molecule [19], so the resulting dimers are 
thus stabilized by bivalent bonds. STAT2 is the only STAT representative that does not act 
as a homodimer, forming instead a complex with STAT1 and p48. As a response to several 
cytokines, the heterodimers STAT1-2, STAT1-3 STAT5A-5B are formed, while no 
heterodimers with STAT 4 and STAT6 have been identified [20] (Table 3). 
Activated STATs dissociate from the receptor, dimerize, translocate to the nucleus and bind 
to members of the GAS (gamma activated site) family of enhancers. There are several more 
recent developments regarding STAT signaling, structural studies, nuclear as well as 
mitochondrial translocation, gene targeting and newly identified regulatory molecules. 
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Classical activation of STATs occurs after cytokine binding to cell-surface receptors that 
initiates a cascade of intracellular phosphorylation events. The phosphorylation of STATs is 
essential not only for dimerization, but also for the concomitant translocation of the dimers 
into the nucleus. Binding of STAT1 and STAT5B to importin-α5, a part of the 
nucleocytoplasmic transport machinery, has been described [21].  
Considering that a second phosphorylation site is serine residue in the c-terminal domain, 
STATs, in addition to tyrosine phosphorylation can be serine phosphorylated by various 
serine kinases [22] that regulate and increase STAT1,3 and 5 transcriptional activity. It is of 
interest that one of the kinases responsible for the phosphorylation of this serine in STAT1 
and STAT3, belongs to the MAP kinases family (ERKs, JNK and p38) which emphasizes the 
important ‘‘cross-talk’’ occurring between the two transductional pathways [23]. 
Furthermore, there is also evidence of the activity of ERK-independent serine kinases [24], 
such as the role of protein kinase C (PKC) in serine phosphorylation of STATs [25] and 
mTOR of the PKI2 pathway. The relative contribution of each of these serine kinases to 
STAT signaling in vivo would depend on cell-type specific expression of kinases [22]. 
Therefore, STATs can be phosphorylated in great many serine/threonine residues, which 
may modulate DNA binding and/or their transcriptional activity [26]. 
One can envision a negative feedback mechanism in which serine phosphorylation of STATs 
promotes the induction of physiologic inhibitors of STAT signaling, such as those of the 
suppressor of cytokine signaling (SOCS) family that inhibit at the level of JAKs [27]. 
Assumingly dual functional role is thus implied for STAT serine phosphorylation events, 
whereby the same serine kinases can apparently both enhance and repress STAT signaling, 
the indirect negative effect being due to preferential association of STAT proteins with the 
serine kinases, precluding interaction with tyrosine kinases [2, 25]. 
In addition to classical, canonical activation by tyrosine phosphorylation, the noncanonical 
STAT activation includes, besides serine phosphorylation, other, phosphorylation-
independent modifications that regulate their activity. In this sense, it has been shown that 
following stimulation of cells with IL-1 plus IL-6 unphosphorylated STAT3 affects gene 
expression in the nucleus through binding to NF-κB that mediates its nuclear import [28]. 
Furthermore, the classical IL-6 mediated activation of STAT3 induces tyrosine-
phosphorylation of STAT3 and activates many genes, including the STAT3 gene itself that 
results in STAT3 synthesis that in its unphosphorylated form can induce not only the 
synthesis of IL-6 but also the expression of other genes such as RANTES, IL-8, Met, and 
MRAS. 
Aside from this, the noncanonical STAT activation includes acetylation of lysine 685 in the 
SH2 STAT domain [29] that occurs in IL-6-induced acute phase reactions [30]. Novel 
findings indicate that acetylation of STAT3 is an important regulatory modification that 
influences protein–protein interaction and its transcriptional activity. Moreover, in 
oncogenesis new data regarding transmembrane glycoprotein CD44 [31], a marker of tumor 
metastatic phenotype, translocates into the nucleus in association with acetylated STAT3 
and by regulating transcription of cyclin D enhances cell proliferation [32] (Fig. 2).  
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Also, many more posttranslational STAT modifications such as isgylation [33], sumoylation 
[34] and ubiquitination [35] are being explored in STAT-dependent tumor formation and 
metastasis. These noncanonical pathways include the many roles of nontyrosine 
phosphorylated STATs, which alter their stability, dimerization, nuclear localization, 
transcriptional activation function, and association with histone acetyltransferases (HAT), 
and histone deacetylases (HDAC) [36] (Fig. 2). 
 
 
Figure 2. Different signaling pathways initiated by phosphorylation of STAT3 on tyrosine or serine 
residues. STAT3 is constitutively imported into and exported from the nucleus independent of its 
phosphorylation status. Oncogenic Ras can stimulate the autocrine production of IL-6, and the resulting 
phosphorylation of STAT3 Tyr705 promotes dimerization and the ability to bind specific DNA target 
sequences. STAT3 can also be phosphorylated on Ser727 and can mediate nuclear import of the NF-κB 
transcription factor. Serine phosphorylated STAT3 stimulates the electron transport chain in 
mitochondria and augments transformation by oncogenic Ras. 
The duration of STATs activation is a temporary process, thus within hours the activating 
signals decay and the STATs are exported back to the cytoplasm. Negative nuclear 
regulators of STATs are nuclear tyrosine phosphatases that induce STAT dephosphorylation 
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in the nucleus important for its export back to the cytoplasm. There is evidence that a 
specific nuclear tyrosine phosphatase (TC45), is a phosphatase relevant for STAT1 and 
STAT3 [37]. In addition, it has been reported that cells lacking this enzyme retain tyrosine 
phosphorylated STAT1 for much longer than normal cells, and overexpression of TC45 
leads to dephosphorylation of STAT5 [38]. However, TC45 has also been implicated in 
regulating cytoplasmic dephosphorylation of JAK1 and JAK3 [39]. 
Recently, the negative activity on STAT protein of a group of nuclear proteins termed 
“proteins that inhibit activated STATs” (PIAS) has been discovered. Studies in cultured 
mammalian cells indicated that PIAS1 and PIAS3 interact only with tyrosine-
phosphorylated STAT1 and STAT3, respectively [40]. PIAS prevents their binding to DNA, 
especially of STAT1, or it speeds-up their degradation in the proteasome. 
Besides nuclear, other phosphatases in the cytoplasm also represent negative STAT 
regulators, they include phosphatases such as SH2-containing phosphatase-1 (SH1), SH2, 
and protein-tyrosine-phosphatase-1B (PTP1B) implicated as cytoplasmic regulators of JAKs 
or STATs’ phosphorylation [38]. 
The activity of STAT proteins is also regulated by the inhibitors of the suppressors of the 
cytokine signal (SOCS) family, responsible for modulating the JAK-STAT pathway by 
acting on the JAK kinases. These cytokine-induced SOCS proteins are recruited to active 
receptor complexes to cause inhibition, and can also cause protein turnover of the 
receptor through a process of proteolytic degradation ubiquitine-proteasome mediated 
[41]. As SOCS belong to the family of target STAT genes they constitute with them a 
classical negative feedback mechanism [12] that can negatively regulate their own 
phosphorylation state [42]. Several members of this family have been identified, 
SOCS1,2,3,4,5,6 and 7. These regulatory proteins have an indirect negative effect on 
STATs by inhibiting their activating enzymes, especially Janus kinases (JAK1, JAK2, JAK3 
and Tyk2), as well as, upstream receptors for growth factors [43]. Considering  
their negative regulatory role, SOCS proteins represent an important intracellular 
mechanism for limiting the potentially adverse effects of  cytokines in immune reactions 
[44]. 
Aside from these mechanisms, mutations that augment the function of their activators or 
decreases the function of their inhibitors may lead to STAT hyperactivity and their 
engagement in malignant transformation. 
Moreover, due to alternate splicing of STAT gene the short forms of STATs, i.e., inactive 
STATβ form, can potentially act as dominant-negative protein and by competitive inhibition 
occupy DNA as non-functional protein without transcriptional capability or by binding to 
wild-type STATs form [45] competitive inhibition, prevent binding of the STATα isoform 
and transcription of target genes. Aside from that, the truncated STATγ isoform of this 
molecule that is created by proteolysis, also competitively inhibits transcription mediated by 
the active α form (Table 3). 
 
STAT Transcription Factors in Tumor Development and Targeted Therapy of Malignancies 463 
Positive regulation of STATs Effects
Canonical regulation of STATs   
 STAT1 - Tyr 701 STAT4 - Tyr 693 
    Phosphorylation of tyrosine STAT2 - Tyr690 STAT5 - Tyr 694 
 STAT3 - Tyr 705 STAT6 - Tyr 641 
Noncannonical regulation of  STATs   
 STAT3 - Ser727  
    Phosphorylation of serine STAT4 - Ser721  
 STAT5 - Ser725/730  
    Unphosphorylated STAT 
IL-6 gene dependant expression 
IL-6 mediated acute phase reactions 
    NFκB Nuclear import of CD44 
    Acetylation   
    Isgylation   
    Sumoylation   
Genetic regulation   
    Mutations     
    Hypermorphic allele of STAT3 Increased transcription  
 Epigenetic regulation   
    Histone acetyl transferase (HAT)   
   
Negative regulation of STATs   
Negative cytoplasmic regulators   
    Tyrosine phosphatase (SHP1,2)   Dephosphorylation  
Protein-tyrosine-phosphatase-1B   
    Suppressors of cytokine signals  
     (SOCS1-7)   
  Inhibit JAK  
  degrade receptors 
 
    Proteases     STAT inactive forms (β and )  
Negative nuclear regulators   
    Nuclear tyrosine phosphatase Dephosphorylation  
    Proteins that inhibit activated STATs 
    (PIAS1-3) 
Inhibits STAT1-3 DNA binding 
Proteasome degradation 
 
    DNA methyltransferase (DNMT) Decreased transcription  
    Ubiquitination Degradation  
Table 3. Regulation of STAT activity 
2. STAT proteins in carcinogenesis 
Aside from their essential role in mediating the effect of cytokines, it has been shown that 
STATs can have a significant role in tumor development and they are being considered as 
potential oncogenes. In normal cells, the activation of STAT proteins is transient, ranging from 
between a few minutes to a few hours. However, in a large group of different tumors constitutive 
activation of STAT family, especially STAT3 and STAT5 members, as well as the loss of 
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STAT1 signaling, has been detected [3, 46]. Novel results indicate that STAT proteins 
regulate numerous pathways that participate in oncogenesis, such as cell cycle progression, 
apoptosis, angiogenesis, tumor invasiveness, metastasis, and immune response evasion. 
Based on this STAT proteins have become significant target molecules in novel therapeutic 
approaches in oncology as blocking of these molecules, directly or indirectly, may arrest the 
malignant process [47]. 
Gough et al. [48] provide evidence that STAT3 has joined a set of transcription factors that in 
mitochondria exhibit noncanonical roles independent of classical STAT3-mediated 
transcription in the nucleus. In this sense, mitochondria have become important in cancer 
research because they regulate proapoptotic and antiapoptotic factors.  
It is also of importance that according to their general principle of action STAT proteins may 
be divided into two groups that differ greatly. The group that comprises STAT2, STAT4 and 
STAT6 is activated by a limited number of cytokines and it is engaged in T cell 
development and the effect of interferons, while the other group that is comprised of 
STAT1, STAT3 and STAT5 is activated in numerous tissues and cell types by great many 
cytokines, different hormones and growth factors and aside from mediating immune 
reactions, regulates many important general processes such as cell proliferation, 
differentiation and survival in embryogenesis, as well as breast development [49]. In that 
sense, this second group of STAT proteins is of importance in malignant transformation. 
Aside from that, earlier results indicated that active STAT1 protein has tumor-suppressor 
characteristics as it down-regulates cell proliferation and induces apoptosis, so that its 
decreased activity is associated with numerous neoplasias. On the other hand, it has been 
shown for STAT3 and STAT5 that they are proto-oncogenes that activate oncogenes, c-
myc, cyklin D and antiapoptotic Bcl-xL protein, facilitate passage through G1/S check-point 
and in that sense, aside from down-regulating apoptosis, enhance cell proliferation and 
transformation [12].  
It has been shown that STAT3 is frequently activated in hematological and epithelial 
malignancies. Constitutive activation of STAT3 leads to proliferation of tumor cells and 
prevents apoptosis, down-regulates the production of numerous proinflamatory cytokines 
and chemokines and leads to secretion of factors that prevent dendritic cell (DC) maturation 
that suppresses adaptive antitumor immunity establishment. Aside from the disturbance of 
the JAK/STAT signaling pathway in primary tumors, a similar finding is frequently found in 
peripheral blood lymphocytes of patients with malignancies [3]. 
2.1. Constitutively activated STATs affect tumor microenvironment 
It is known that invasive tumors need to modulate gene expression in a manner that impairs 
the activity of innate and adaptive immunity in immune surveillance [50, 51]. STAT3 
positive tumors achieve this by preventing the production of proinflamatory cytokines, i.e., 
“danger signals”. Activation of the transcription factor STAT3 in the tumor and adjacent 
immune cells, including tumor associated macrophages (TAMs),T regulatory cells (Treg 
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cells), DCs, Th1 cells, Th2 cells, B regulatory cells (Bregs), myeloid derived suppressor cells 
(MDSCs), Th17 cells, as well as, normal epithelial cells, lead to production of cytokines IL-
1β, IL-6, IL-10, IL-17, as well as VEGF creating a feedback loop that promotes tumor growth,  
angiogenesis, evasion of immune surveillance and metastasis [52]. 
It has been shown that especially tumor produced IL-6 through JAKs/STAT3 signaling has 
an important role in modulating the tumor-associated immune microenvironment. IL-6 has 
pleiotropic functions by activating numerous cell types expressing membrane-bound gp130 
IL-6 receptor, i.e., classical IL-6 signaling, as well as, by soluble form of the IL-6 receptor 
(sIL-6 receptor) that after binding IL-6 and interaction with gp130 in the form of IL-6 trans-
signaling modulates a broad spectrum of target cells including epithelial cells, neutrophils, 
macrophages, and T cells [53]. Upregulated STAT3 in TAM has been shown to enhance the 
expression of IL-23 that leads to the expansion of Tregs, while conversely, transcriptionally 
repressing IL-12 that supports proinflamatory cytokines and antitumor immune reactions 
within the tumor milieu [54]. Also, tumor-evoked Bregs express activated STAT3 and 
induce TGFβ conversion of Tregs from resting T cells [55] (Fig.3). Therefore, the production  
 
Figure 3. Interaction between tumor cells and tumor microenvironment mediated by cytokines.  Tumor 
cells and different immune cells including TAMs, Treg cells, DC, Th17 cells, and non-tumor (normal 
epithelial) cells undergo STAT3 activation under the effect of various cytokines, and in turn produce 
more cytokines forming a feedback loop. STAT3 also regulates cell proliferation, cell cycle progression, 
apoptosis, angiogenesis together with immune evasion. Inhibition of STAT signaling could eliminate 
tumor cells while exerting minimal effect on the normal cells. Preclinical models have validated STAT3 
as a target for cancer therapy, although only indirect JAK inhibitors have advanced to clinical trials 
(Cytokines that induce STAT3 activation are written in bold letters). 
 
Oncogene and Cancer – From Bench to Clinic 466 
and release of various survival factors, including IL-6 as a major activator of  STAT3, also 
serve to block apoptosis in cells during the inflammatory process, keeping them alive in 
very toxic environments. Unfortunately, at the same time these same pathways serve to 
maintain cells progressing towards neoplastic growth, protecting them from cellular 
apoptotic deletion and chemotherapeutic drugs. 
It is of importance that activation of STAT3 within tumors is heterogeneous and it has been 
found that pSTAT3 are highest on the leading edge of tumors and that this is associated 
with stromal, immune, and endothelial cells. This follows from IL-6 from cancer-associated 
fibroblasts or myeloid cells that in a feedback loop induces autocrine production of IL-6 and 
pSTAT3 expression in tumor cells, thus also leading to heterogeneous levels of pSTAT3 [56]. 
Therefore tumor STAT3 activity can mediate tumor immune evasion and induce tolerance 
rather than immunity by blocking both the production and sensing of inflammatory signals 
by components of the innate and adaptive immune systems that have been recently defined 
as “extrinsic tumor suppressors” [57]. 
Regarding tumor microenvironment, in physiological conditions the activation of STAT3 is 
of paramount importance during tissue remodeling in the process of „wound healing“ [58]. 
As tumor growth also includes tissue damage, the dysregulation of STAT3 in the context of 
tumor microenvironment has a detrimental effect that instead of wound healing leads to 
further tissue destruction, together with evasion of immune response. 
2.2. STATs support oncogene-dependent cellular transformation 
Oncogenes can only transform cells that have been immortalized by carcinogens or other 
oncogenes exemplifying the paradigm of multistep carcinogenesis. In this sense, mammal 
cells transformed by oncogenic src show constitutively active STAT3 and negative-dominant 
forms of STAT3 block the transforming ability of src, demonstrating a close correlation 
between STAT3 activation and the oncogenic transformation by this oncogene [59]. 
Moreover, recent studies have shown that constitutive activation of STAT3 in human breast 
cancer cells correlates with EGFR family kinase signaling and also with aberrant JAK and 
Src activity [60]. In addition to Src, many other transforming tyrosine kinases, such as Eyk, 
Ros and Lck, constitutively activate STAT3 in the context of oncogenesis. Another example 
of tumorigenic stimuli known to activate STAT proteins is Abl that may constitutively 
activate STAT3 and STAT5, whereas the fusion protein, Bcr-Abl, may activate them in the 
absence of constitutive JAK activation, showing that the presence of the JAK kinases is not 
always essential for STAT activation [2] (Table 4). 
In addition to its previously characterized nuclear roles, transformation specific function for 
mitochondrial STAT3 has now been shown. Although previous data implicated a Ras-
STAT3 axis in transformation, those cases were in the context of activated tyrosine kinases, 
such as NPM-ALK [61], RET [62], or autocrine cytokine signaling requiring STAT3 function 
in the nucleus. However, it has now been shown that for cellular transformation and 
anchorage-independent growth induced by activated H-, N- or K-Ras, STAT3 
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phosporylated on Serine727 and expressed exclusively in mitochondria was required. In 
contrast, recent findings also show that mitochondrially restricted STAT3 did not support 
src-driven anchorage-independent growth, consistent with former data that src requires 
nuclear functions of STAT3 [63]. 
 
Cell type Oncogene Activated STATs 
Fibroblasts v-Src 
c-Src 
v-Sis 
v-Ras 
v-Raf 
IGF-1 receptor 
STAT3 
STAT3 
STAT3 
 
 
STAT3 
Myeloid v-Src STAT1, STAT3, STAT5 
T cell Lck  STAT3, STAT5 
Mammary/Lung epithelial v-Src STAT3 
Gallbladder adenocarcinoma v-Src STAT3 
Pre-B lymphocytes v-Abl STAT1, STAT5 
Erythroleukemia/blast cells/ 
basophils/mast cells
Bcr-Abl STAT1, STAT5 
Primary bone marrow Bcr-Abl STAT5 
Table 4. STAT activation by oncogenes 
Mitochondrial STAT3 contributes to Ras-dependent cellular transformation by augmenting 
electron transport chain activity, particularly that of complexes II and V, accompanied by 
energy production to favor cytoplasmatic glycolysis that represents a hallmark of cancer 
formulated in the 1950’s by Warburg [64]. Additional analyses are required to understand 
the connections between glycolysis and oxidative phosphorylation affected by STAT3 in the 
presence or absence of oncogenic Ras. 
STAT3 apparently enters mitochondria associated with GRIM-19 that was identified as a 
subunit of the mitochondrial complex I and Ser727 appears to be needed for their interaction 
[65]. 
Therefore, the “metabolic shift” important for tumor growth mediated by mitochondrial 
STAT3 may reflect exploitation of a normal function and in this sense mitochondrial STAT3 
function could provide a new target for therapeutic approaches to cancer [65]. 
2.3. Anti-oncogenic and oncogenic characteristics of STAT1  
STAT1 has been considered to be an anti-oncogene, i.e., tumor-suppressor protein that 
blocks proliferation and induces apoptosis [66]. Moreover, it has been shown that its 
dysfunction leads to the loss of immune surveillance [67]. Loss of STAT1 supports 
angiogenesis and metastasis of tumors. 
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It has been established that STAT1, the first STAT to be discovered, is required for signaling 
by the IFNs which in addition to their role in innate immunity, serve as potent inhibitors of 
proliferation and promoters of apoptosis. The involvement of STAT1 in growth arrest and 
apoptosis in many cell types may be explained by its capacity to induce caspase and p21 
expression [68] and reduce c-myc expression. Although, normally, high p21 expression is 
associated with cell growth arrest, p21 increase has also been observed in some human 
neoplasias. This contradiction has been explained by Bowman et al. (2000) [2] with the fact 
that p21 is also responsible for the correct association of the cyclin D1/CDK cyclin complex, 
and thus its increase may be necessary for cell-cycle progression. Interestingly, in mammary 
cells p21 upregulation by STAT1 appears to involve BRCA1, which is often lost in familial 
and other forms of breast cancer. Effective STAT1-BRCA1 binding is mediated by serine 
phosphorylation of STAT1. More recently besides its role as tumor suppressor, new 
evidence has shown that STAT1 can be activated in some malignancies such as breast, lung, 
head and neck cancer and brain tumors [46]. In this sense, STAT1 tyrosine 701 
phosphorylation increase was demonstrated in human breast tumor cells with elevated 
levels of HER-2/Neu as well as in cell lines transfected with HER-2/Neu gene [70]. However, 
it is of interest that breast cancer patients with higher levels of phosphorylated and DNA-
bound STAT1 show better prognosis and live longer. 
Besides increased STAT activation, high expression of the unphosphorylated form of STAT1 
was also found in cancer cells. Moreover, it has been also shown that recurrent tumors 
express higher levels of unphosphorylated STAT1 compared to the original tumors [72], as 
well as cancer cells resistant to ionizing radiation and anticancer agents [73]. Recently, 
functions of some STAT1-induced genes in cancer cells have been investigated, and some 
have been shown to have pro-metastatic, pro-proliferative, or antiapoptotic properties [74]. 
In this sense it has been found in melanoma cells that high levels of STAT1 expression 
inhibits caspase 3/7 activation in response to doxorubicin which contributes to patients' 
resistance to this chemotherapeutic agent [75]. It has also been shown by Khodarev et al. 
(2007) [76] that ectopically increased expression of STAT1 can induce a radiation-resistant 
phenotype. 
Both type I and type II IFNs increase STAT1 expression in many cell types, including normal 
fibroblasts and mammary epithelial cells, and the newly synthesized STAT1 protein persists 
for many days after IFN stimulation in unphosphorylated form [77]. Certain types of human 
tumors are unresponsive to IFNs due to defects in the STAT1 activation pathway. 
Contrary to these findings, recent data states that the expression level of STAT1 does not 
influence the response to IFN adjuvant therapy in cancer [72] and that the overexpression of 
STAT1 in recurrent tumors might be caused by IFN treatment. In these tumor cells the 
found increase in STAT1 level does not result in enhanced anticancer effects of STAT1 as 
many IFN-induced pro-apoptotic and antiproliferative proteins as APO2L/TRAIL and IRF1 
[78] are not upregulated in resistant cells. This strongly indicates that IFN signaling is not 
responsible for STAT1 upregulation in cancer cells. It has also been found that high level of 
unphosphorylated STAT1 in tumors protects cancer cells from DNA damage [79]. 
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These observations suggest that increased levels of unphsphorylated STAT1 might 
participate in oncogenesis as well as resistance to cell death by inducing target genes that 
increase proliferation, decrease cell death, or increase repair of DNA damage. Increased 
DNA damage in cancer is due to oncogene-induced damage, chromosome instability, and 
other causes that are intrinsic to tumorigenesis. Therefore, evolving cancer cells must learn 
to resist the consequences of DNA damage, avoiding normal cellular responses such as cell 
cycle arrest or apoptosis, thus relying on support mechanisms that are characteristic for the 
tumor “stress phenotype”. A working hypothesis that is now being formulated is that the 
increase in STAT1 expression in cancers is due to processes intrinsic to tumorogenesis [77]. 
2.4. Oncogenic characteristics of STAT3 and STAT5 
Although STAT3 was originally identified as an acute phase response factor that is activated 
after stimulation by interleukin-6 (IL-6) [65], the biological functions of STAT3 are diverse, 
in part stemming from the activation of STAT3 by a wide range of cytokines, growth factors, 
as well as oncogenes. Among its many effects, it is now known to promote oncogenesis, 
while a hypermorphic allele of STAT3 can function as an oncogene [10]. 
It is established that the basic role of STAT3 in tumors is the prevention of apoptosis that is 
achieved by increased expression of antiapoptotic molecule, Bcl-2, or by affecting cell cycle 
progression by increased expression of c-myc and cyclin D1 engaged in the transition 
through G1/S check point. This is a characteristic of tumor cell lines with deleted STAT3 
gene (STAT3 -,-) where the lack of STAT3 activity leads to the appearance of apoptosis due 
to an increase in the level of caspases, and a decrease in the level of Bcl-2, while down-
regulated proliferation follows from decreased level of cycline D i c-myc oncogenes. 
In contrast to normal cells, in which STAT tyrosine phosphorylation occurs transiently, it has 
been determined that STATs 1, 3, and 5 are persistently tyrosine phosphorylated in most 
malignancies (particularly STAT3) [2, 46]. The mechanisms by which STAT3 is persistently or 
constitutively tyrosine phosphorylated in cancers include increased production of cytokines 
and cytokine receptors, which is initiated by tumor cells in an autocrine, and by tumor 
microenvironment in a paracrine manner, by a decrease in the expression of the SOCS proteins 
through gene promoter methylation, as well as loss of tyrosine phosphatase activity [11]. 
Most of the described oncogenic functions of STAT3 depend on the phosphorylation status 
of Tyr705, however, another role of STAT3 is independent of tyrosine phosphorylation, as 
unphosphorylated STAT3 can also affect gene expression in the nucleus, one mechanism is 
through binding to NF-κB and mediating its nuclear import [80]. 
STAT3 has been directly linked to human cancer as it is required for cell transformation by 
the src oncogene [81], as well as in promoting cellular transformation by the H-ras oncogene. 
This function, which is dependent on the noncanonical serine phosphorylation of STAT3, 
takes place in mitochondria. 
Unlike another member of STAT family, STAT1, that is imported in the nucleus only in 
phosphorylated form, STAT3 dynamically shuttles in and out of the nucleus independent of 
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its tyrosine phosphorylation status [82, 83]. Nuclear import requires binding of STAT3 to an 
importin-α−importin-β dimer. On the other hand, mitochondrial import could be mediated 
in several ways, including by association with the cytosolic chaperones, heat shock proteins 
(Hsp70, Hsp90) [84] or associated with GRIM-19, a subunit of mitochondrial complex I of 
the electron transport chain [85] engaged in cell death processes in mitochondria that when 
overexpressed inhibits the activity of STAT3 by direct binding [86]. 
In light of this finding and the fact that STAT3 function has been linked to cancer, Gough et 
al. (2009) [48] evaluated the contribution of STAT3 to Ras oncogenic transformation. Ras 
protooncogenes become constitutively active oncogenes with the acquisition of specific 
point mutations [87], which stabilize Ras binding to guanosine 5´-triphosphate (GTP), thus 
allowing Ras in its GTP-bound state to stimulate numerous downstream effectors. However, 
Ras oncogenes can only transform cells that have been immortalized by carcinogens or other 
oncogenes, in the classical multistep carcinogenesis. Some of the signaling molecules 
activated in response to Ras can impact the STAT3 transcription factor. For example, 
mitogen-activated protein kinases (MAPKs) can phosphorylate STAT3 on Ser727 and 
downstream activation of the NF-κB transcription factor induces autocrine IL-6 production 
canonical tyrosine phosphorylation of STAT3 [88]. 
Cancer cells tend to have reduced oxidative phosphorylation in mitochondria, and have 
increased glycolysis in the cytoplasm leading to lactate production [89]. STAT3, inspite of its 
role in cellular transformation and cancer, promotes oxidative phosphorylation in 
mitochondria. New findings show that Ser727 phosphorylation of STAT3 contributed to 
oxidative phosphorylation  in mitohondria. The effect of STAT3 on oxidative 
phosphorylation in mitochondria was investigated by comparing enzyme activity in 
STAT3+/+ to STAT3−/− cells [48]. Wegrzyn et al. (2009) [90] showed that STAT3+/+ cells had 
comparatively greater activity of electron transport complex I and complex II but no 
difference in the activities of complex III or complex VI. Comparing Ras-transformed 
STAT3+/+ and STAT3−/− cells revealed that, the presence of STAT3 increased activities of 
electron transport complex II and V. Analogous to cells that lack oncogenic Ras [90], STAT3 
appears to stoke the powerhouse, i.e., mitochondria.   
Unexpectedly, STAT3-expressing cells also had decreased mitochondrial membrane 
potential and increased lactate dehydrogenase production, indicating a shift to cytoplasmic 
glycolysis. Additional analyses are required to understand the complex connections 
between glycolysis and oxidative phosphorylation affected by STAT3 in the presence or 
absence of oncogenic Ras. 
Originally, STAT5 was originally identified as a specific transcription factor that mediates 
the effects of prolactin [91]. STAT5A and STAT5B forms are 96% conserved at the protein 
level but they differ in their C terminal domain as STAT5A has 20 and STAT5B 8 unique 
amino acids in the C-terminus [92]. However, STAT5A transmits predominantly the signals 
initiated by the prolactin receptor, while STAT5B mediates the biological effects of growth 
hormone. 
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The most important role of STAT5A and STAT5B is in lymphoid, myeloid and erythroid cell 
development and function as they are activated by multiple cytokines, including IL-2, IL-3, 
IL-5, IL-7, IL-9, IL-15, GM-CSF and erythropoietin [93]. STAT5B serine 193 is a novel 
cytokine induced phospho-regulatory site that is constitutively activated in primary 
hematopoietic malignancies [94]. Following cytokine stimulation, human STAT5A and 
STAT5B are phosphorylated by JAK1, JAK2 or Tyk on the conserved tyrosine residues 694 
and 699, respectively, which allows for their dissociation from the receptor complex, 
formation of hetero- or homo-dimers, and nuclear translocation to bind specific elements in 
the promoter of target genes and activate transcription [95]. While tyrosine phosphorylation 
is a part of activation signal, the serine 726 on STAT5A and 731 on STAT5B phosphorylation 
may abrogate the transcriptional activity of STAT5A/B [96]. 
In addition to the physiological role of STAT5 in hematopoietic cell development, 
dysregulation of the STAT5 signaling pathway plays a role in oncogenesis and 
leukemogenesis [97]. Specifically, STAT5 has been shown to be constitutively activated in 
several forms of lymphoid, myeloid and erythroid leukemia [98-100]. Persistent activation of 
STAT5 was found to be a result of deregulated cytokine signaling [101] or the presence of 
oncogenic tyrosine kinases. STAT5 proteins can activate many oncogenic tyrosine kinases, 
including Bcr-Abl, mutated forms of Flt-3 and Kit, and the JAK2 V617F mutant [102-104]. In 
acute promyelocytic leukemia (APL) beside the most common PML-RARα chromosomal 
translocation, RARα gene can be fused with STAT5B forming a fusion protein that blocks 
myeloid differentiation [105]. 
The most probable molecular mechanism by which STAT5 promotes tumorogenesis is 
upregulation of cyclin D and c-myc expression which promotes progression from the G1 to 
the S-phase of the cell cycle [2]. Aside from stimulating proliferation, STAT5 inhibits 
apoptosis by inducing the expression of anti-apoptotic Bcl-xl protein and promotes survival 
of tumor cells [106].  
In addition to several types of leukemia and hematopoietic disorders [8], active STAT5A/B is 
also frequently detected in solid tumors, such as prostate cancer, breast cancer, uterine 
cancer, squamous cell carcinoma of the head and neck [107]. 
STAT5A/B controls viability and growth of prostate and breast cancer. The expression of 
nuclear, active STAT5A/B is often associated with high grade prostate cancer, predicts early 
disease recurrence and promotes metastatic dissemination. In prostate cancer, active 
STAT5A/B signaling pathway increases transcriptional activity of androgen receptors. 
Androgen receptor, in turn, increases transcriptional activity of STAT5A/B. STAT5A/B 
potentially contributes to castration resistant growth of prostate cancer [108]. The molecular 
mechanisms underlying constitutive activation of STAT5 in primary and recurrent human 
prostate cancers are currently unclear, and may involve the autocrine prolactine–JAK2 
pathway [109], Src kinases, or Rho GTPases.  
In breast cancer, the role of STAT5A/B is more complex. In rodent model systems STAT5A/B 
may promote malignant transformation and enhance growth of breast tumors [110], while in 
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contrast, STAT5A/B activation in established human breast cancer positively correlates with 
tumor differentiation [111], prevents metastatic dissemination, and predicts favorable 
clinical outcome [112] of node-negative breast cancer. In addition, active STAT5A/B, 
induced by Akt-1, positively correlated with mammary epithelial cell differentiation and 
possibly a better response to endocrine therapy [113]. Collectively, these studies suggest a 
dual role for STAT5A/B in the mammary gland as an initiator of tumor formation, as well as 
a promoter of differentiations of established tumors.  
2.5. STAT dysfunction associated with different malignancies 
In addition to individual roles of each STAT, they may be coactivated in cancers. In this 
sense, STATs 1, 3, and 5 are simultaneously tyrosine phosphorylated in a number of human 
cancers including breast, lung, and head and neck tumors (Table5). The presence of pSTAT5 
in addition to pSTAT3 in head and neck tumors can enhance tumor growth and invasion 
and may contribute to resistance to EGFR inhibitors and chemotherapy [114]. 
The functional interplay between activated STAT3 and STAT5 has also been described in 
breast cancers. Considering that STAT3 is included in breast development in association 
with EGFR, it has been shown on breast cancer cell lines and primary tumors that EGFR 
mutations, as well as the activity of src proto-oncogene, lead to hyperactivity and STAT3 
oncogenic properties [115]. JAK/STAT3 signaling pathway is required for growth of 
CD44+CD23- breast cancer stem cells in tumors [116]. It has been shown that STAT1 
blocking by EGFR in this tumor, unlike inhibition of STAT3, does not show any influence on 
cell proliferation [117].  
Activated STAT3 and IL-6 are preferentially found in triple-negative breast cancers or in 
high-grade tumors and are associated with poor response to chemotherapy [118]. In human 
tumors, however, the presence of pSTAT5 is found predominantly in well-differentiated 
estrogen receptor (ER)–positive tumors and is associated with favorable prognosis. 
Furthermore, the presence of pSTAT5 is a predictive factor for endocrine therapy response 
and strong prognostic molecular marker in ER-positive breast cancer. Tumors expressing 
both activated STAT3 and STAT5 were more likely to be ER positive and human EGFR2 
negative and of a lower stage.  
Aside from the detected STAT dysregulation in tumors, more recent data report STAT status 
in peripheral blood lymphocytes (PBL). Results of an investigation of STATs in PBL of 
patients with breast cancer indicates constitutive, as well as stage-dependent, decrease in 
STAT1, STAT3, STAT5 expression and impaired induction of these proteins by Th1 
cytokines [119]. The commonly found dysfunction of NK cells in breast cancer patients [120-
122] is probably the consequence of cytokine dysbalance due to the prevalence of 
immunosuppressive cytokines such as IL-10 and TGFβ [123], as well as tumor-produced 
inhibitory factors [124]. This finding is in concordance with the only previous study 
published for breast cancer patients [125] and also with several other investigations showing 
STAT dysregulation in PBL of melanoma and renal cell carcinoma patients [126,127]. 
Moreover, we showed that breast cancer patients’ T and NK cell subsets have lower pSTAT1 
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level that could be a biomarker of decreased NK cell cytotoxicity and IFNγ production 
associated with progression of this disease [120, 128,129]. 
Constitutively active STAT3 present in breast cancer and many human solid tumors, is 
associated with immunosuppression of the host immune response. STAT3 expression 
promotes the production of IL-1β, IL-6, IL-10, TGFβ and VEGF by tumor cells [130] leading 
to STAT3 activation in immune cells and in turn production of more cytokines forming a 
feedback loop. These cytokines also inhibit dendritic cell maturation, exerting a pro-tumor 
response. In this sense, evaluation of STATs in PBL is of importance in predicting the 
possibility of immunomodulatory and antitumor effect of immunotherapy with cytokines in 
patients with malignancies. 
Constitutive activation of STATs has been detected in human head and neck squamous 
carcinoma cells [131]. In these cells, activation of STATs is dependent on TGFα induced 
activation of EGFR and studies utilizing antisense oligonucleotides have demonstrated that 
STAT3 mediates oncogenic growth of these cells. Activation of STATs in non-small cell lung 
carcinoma (NSCLC) increased production of TGFα by activating EGFR tyrosine kinase [132] 
induces downstream STAT3 activation and engages it in the pathogenesis of this 
malignancy. EGFR constitutive activation of STATs has also been detected in prostate, renal 
cell, lung, ovarian, and pancreatic cancers, as well as melanomas.  
In addition, activation of src also occurs with elevated frequency during progression of 
human breast, ovarian and prostate cancer, and EGFR and Src have been shown to 
cooperate in human breast cancer [133]. Aside from that, it is of importance that in prostate 
cancer cell lines the role of BRCA1 gene has been shown in forming of hyperactive STAT3 
[134]. When castration resistant disease develops in androgen receptor (AR) positive 
prostate cancer, these tumors often express higher levels of AR, possibly through activated 
STAT3, which can transcriptionally regulate AR. Thus, combining antiandrogens with anti- 
STAT3 drugs should be considered, rather than with chemotherapy in hormone-refractory 
metastatic prostate cancer [11]. Also, in B16 mouse melanoma cell line hyperactive STAT3 
has also been detected [135] (Table 5). 
STAT hyperactivity has been demonstrated in lymphomas and leukemias. In acute myeloid 
leukemia (AML), characterized by the presence of immature myeloid cells in the bone 
marrow, STAT3 and STAT5 hyperactivity has been found. This may follow from an 
overproduction of hematopoietic cytokines by tumor cells [136]. An increased level of 
STAT3β isoform in leuekimic blasts in the bone marrow has been found in patients with this 
leukemia that have an overall shorter time of survival [137]. It is presumed that STAT5 in 
AML is activated by mutations in the flt-3 gene. It has also been shown that hyperactive 
STAT3 induces increased production of VEGF in bone marrow of acute and chronic 
leukemia. This is in accord with the common finding of increased blood vessel density in 
bone marrow in these malignancies [138]. Constitutive activation of STATs 1 and 5 has been 
additionally detected in acute myelogenous leukemia (AML) and chronic myelogenous 
leukemia (CML) cells possessing the activated Bcr-Abl tyrosine kinase [139]. Moreover, T 
cell leukemia that arise in HIV infections, as well as Hodgkin’s disease, express active 
STAT3. 
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Tumor type Activated STAT proteins  
Solid tumors   
Breast cancer STAT1,STAT3, STAT5  
Head and neck cancer STAT1,STAT3, STAT5  
Melanoma STAT3  
Lung cancer STAT3,STAT5  
Ovarian cancer STAT3  
Pancreatic cancer STAT3  
Prostate cancer STAT3,STAT5  
   
Hematological malignancies   
Acute myelogenous leukemia  STAT1,STAT3  
HTLV-1 dependent leukemia STAT3,STAT5  
Multiple myeloma STAT1,STAT3, STAT5  
Acute lymphoblastic leukemia  STAT5  
LGL leukemia STAT3  
Chronic myelogenous leukemia  STAT5  
   
Lymphomas   
Cutaneous T cell lymphoma  STAT3  
EBV-related and Burkitt's lymphoma  STAT3  
B-cell non-Hodgkin's lymphoma STAT3  
Anaplastic LGL lymphoma STAT3  
Table 5. Activated STAT proteins found in various solid and hematologic tumors 
The constitutive activation of STAT3 is more striking than STAT5 in ALK+ anaplastic large 
T-cell lymphoma (ALCL). In Sezary Syndrome, a leukaemic form of cutaneous T cell 
lymphoma (CTCL), the JAK3-STAT3 pathway is constitutively activated, while STAT5 
activation is inducible [140]. In APL, aside from characteristic RARα - PML chimeric fusion 
protein, the novel translocation resulting in STAT5B - RARα is considered to be responsible 
for the lack of response to ATRA-mediated prodifferentiation therapy [141]. Moreover, 
inadequate activity of STAT4 leads to T helper 2 (Th2) cytokine (IL-4, IL-5 and IL-10) 
production and prevents adequate antitumor immune response.  
3. STATs as therapeutic targets  
As malignant tumors are now treated, aside from standard chemo and radiation therapy, by 
novel therapeutic approaches based on tumor molecular profile, therapy of different tumors 
now includes agents for specific targeted therapy designed to neutralize pathogenic 
mutations, a goal that is complex and in development. For this reason, novel therapy has 
extended to transcription factors, such as STATs, and agents have been designed that 
directly or indirectly block oncogenic STAT3 and STAT5 activity. 
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Following extensive cell-based screening systems for these agents in different normal, gene 
modified and malignant cell lines, as well as studies in experimental animals, it has been 
established that oncogenic STATs may be inhibited in a direct manner. One of the means is 
by decreasing STAT gene expression by antisense oligonucleotides (DNA and RNA) or by 
blocking STAT3 and STAT5 activity by small inhibitory molecules and peptide analogues. 
These STAT inhibitory agents have been most commonly designed to target the domains 
responsible for STAT dimerization , i.e., the  N-terminus domain and the Src homology 
(SH2) domain, as well as the DNA-binding domain that makes physical contact with the 
STAT-responsive elements in the promoters of target genes [142] (Figure 4). 
 
Figure 4. Available approaches and strategies to target STAT signaling pathways. These approaches 
target directly or indirectly STAT signaling in tumors and include interfering with STAT3 and/or 
STAT5 expression, phosphorylation, degradation, inhibition of receptor and non-receptor tyrosine 
kinases, direct interaction with STAT proteins intended to disrupt dimerization, and finally approaches 
to inhibit DNA-binding activity and gene transcription. These strategies should lead to a decrease in 
STAT signaling activity and even lower their level to normal values.  
On the other hand, hyperactive STAT molecules can also be inhibited indirectly by 
inhibiting up-stream, either receptor or non-receptor tyrosine kinases that drive tyrosine 
phosphorylation and activate STATs leading to their hyperactive state [143]. In this sense, 
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aside from JAK enzyme inhibitors, in use are also inhibitors of src oncogene and  inhibitors 
of EGFR enzymatic activity, including tyrosine kinase inhibitor gefitinib, and imatinib, an 
inhibitor of bcr-abl oncogene characteristic for CML, as well as passive immunotherapy with 
antibody for IL-6 or its receptor [47].  
JAK enzyme inhibitors, such as tyrphostine AG490, have been shown in clinical trials to be 
effective in the therapy of multiple myeloma and other hematological malignancies and 
solid tumors with aberrant activation of the JAK-STAT signaling pathway [144]. Other 
agents of this type, including ruxolitinib, by showing promising results in phase III clinical 
trials for myelofibrosis provide a basis for their study in solid tumors such as prostate 
cancer. In addition to improved outcome, many JAK inhibitors have been found to be 
tolerable with no adverse impact on the quality of life of patients possibly due to 
redundancies in signaling downstream of cytokine receptors, with STATs being only a part 
of the signaling network. 
Considering both the crosstalk between STAT and other signaling pathways and activation 
of other pathways by STAT inhibiting agents, such as activation of Erk MAPK kinases 
during pimozide STAT5 inhibitor therapy, therapeutic modalities may include STAT 
inhibitors in combination with MEK inhibitors, an approach defined as complementary 
signaling pathway inhibition [145]. Although STAT inhibitors may decrease expression of 
pro-survival genes, this may not be sufficient to induce apoptosis, but may merely lower the 
threshold for apoptosis. In this sense, a STAT inhibitor may reduce resistance to cytotoxic 
agents or ionizing radiation and may best be used in combination with standard therapies. 
Other indirect methods for inhibition include modulation of the activity of STAT molecule 
by using their natural negative regulators. Thus, the activity of these signaling molecules is 
suppressed by increased protease activity, especially for hyperactive STAT5, induction of 
nuclear and cytoplasmatic STAT inhibitory proteins, SOCS and PIAS, respectively, or up-
regulation of tyrosine-phosphatases that dephosphorylate them [146]. Application of statins, as 
trichostatin A, leads to inhibition of enzyme histone deacetylase (HDAC) that by decreasing 
STAT transcriptional activity promotes apoptosis of malignant cells, whereas direct binding of 
statins to STATs leads to their covalent modification and enhanced degradation [147].  
In this sense, different approaches in the context of modern targeted therapy of 
malignancies by decreasing expression, phosphorylation, dimerization or DNA binding of 
STATs can decrease the activity of these important signaling molecules or down-regulate 
them to almost normal level. Considering that inhibition of STAT3 and STAT5 leads to 
growth arrest and selective apoptosis of tumor cells, sparing benign cells, this approach may 
be of importance not only in the therapy, but also in chemoprevention of tumors. These 
aspects of molecular targeted therapy of cancer patients need to be validated in additional, 
properly designed clinical trials. 
4. Conclusion 
As STAT proteins are involved in regulating fundamental biological processes, including 
apoptosis and cell proliferation that are known to be dysregulated in tumors, it is not 
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surprising to frequently find defects in STAT signaling pathways in malignancies. In the 
past few years advances have been made in understanding molecular mechanisms that are 
responsible for STAT protein dysregualtion in different malignant diseases. The critical role 
of constitutively active STAT3 and STAT5 in tumorogenesis has now been definitely 
established. Aside from that, STAT1, 3 and 5 can be considered as molecular markers for 
early detection of certain tumors, as well as prognostic parameters for evaluation of  tumor 
aggressiveness and response to various types of therapies. 
Obtained data that associate these molecules with tumor development support the use of 
STATs as molecular targets in the therapy and chemoprevention of malignancies. Inhibition 
of oncogenic STATs represents a comprehensive approach in tumor therapy that leads to 
decreased cell proliferation, survival, angiogenesis and evasion of immune response. 
Blocking of constitutively active STATs in tumors allows the destruction of tumor cells with 
minimal effect on normal cells. It is of importance that this type of molecular therapy that 
inhibits hyperactive STATs can potentiate response to chemo or radiation therapy and may 
have great potential in the therapy of solid tumors and leukemia. The efficacy of STAT 
inhibitors in oncological therapy remains still to be evaluated in numerous undergoing and 
future clinical trials. 
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